je.st
news
Five Prime Therapeutics: Ridiculously Undervalued
2015-10-17 20:45:28| Biotech - Topix.net
Five Prime trades at a ridiculously low enterprise value of ~ $280 Million after a $1.74 Billion deal with Bristol Myers Squibb. Five Prime is sitting on ~$520 Million in cash and still has a highly effective discovery platform and wholly owned assets.
Tags: prime
therapeutics
undervalued
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||